Santillana JA, Chávez PCE, Muñoz RMR, Sánchez NVM

Language: Spanish
References: 13
Page: 315-318
PDF size: 139.40 Kb.

ABSTRACT

Introduction: Venous thromboembolism is a preventable cause of death in critically ill patients. The most common thromboprophylaxis strategy is the use of low molecular weight heparins, however it is not known which is superior. Bemiparin shows a favorable pharmacologic profile.
Objective: Evaluate the safety profile of bemiparin thromboprophylaxis in the critically ill.
Materials and methods: This retrospective observational trail was carried out in an adult intensive care unit. Patients hospitalized between December 2013 and June 2015 receiving bemiparin throboprophylaxis were included. The presence of major bleeding, thrombocytopenia and the correlation between dose and adverse events was noted.
Results: 111 critically ill patients received bemiparin thromboprophylaxis No episodes of venous thromboembolism were recorded. 6.3% of patients had a major bleeding episode during their intensive care unit stay. The incidence of severe thrombocytopenia was 1.8%, while 8.6% of patients had a platelet count decrease typical of heparin induced thrombocytopenia, no cases were recorded. Adverse events were not associated with bemiparin dose.
Conclusions: The safety of bemiparin thromboprofilaxis is similar to that of other Low Molecular Weight Heparins (LMWH) in critically ill patients.

REFERENCES

1. Vincent JL, Abraham E, Kochanek P, Moore FA, Fink MP (eds.). Textbook of critical care. 6ta ed. Saunders-Elsiever. 2011.

2. Huang W, Anderson FA, Rushton-Smith SK, Cohen AT. Impact of thromboprophylaxis across the US acute care setting. PLoS One. 2015;10(3):e0121429.

3. Ciccone MM, Cortese F, Corbo F, Corrales NE, Al-Momen AK, Silva A, et al. Bemiparin, an effective and safe low molecular weight heparin: a review. Vascul Pharmacol. 2014;62(1):32-37.

4. Kahn SR, Lim W, Dunn AS, Cushman M, Dentali F, Akl EA, et al; American College of Chest Physicians. Prevention of VTE in nonsurgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e195S-226S.

5. PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, et al. Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med. 2011;364(14):1305-1314.

6. Crowther MA, Cook DJ, Meade MO, Griffith LE, Guyatt GH, Arnold DM, Rabbat CG, Geerts WH, Warkentin TE. Thrombocytopenia in medical-surgical critically ill patients: prevalence, incidence, and risk factors. J Crit Care. 2005;20(4):348-353.

7. Alhazzani W, Lim W, Jaeschke RZ, Murad MH, Cade J, Cook DJ. Heparin thromboprophylaxis in medical-surgical critically ill patients: a systematic review and meta-analysis of randomized trials. Crit Care Med. 2013;41(9):2088-2098.

8. Chapman TM, Goa KL. Bemiparin: a review of its use in the prevention of venous thromboembolism and treatment of deep vein thrombosis. Drugs. 2003;63(21):2357-2377.

9. Marik PE (ed.). Evidence-based critical care. 3ra ed. Springer International Publishing. 2015.

10. Navarro-Quilis A, Castellet E, Rocha E, Paz-Jiménez J, Planès A; Bemiparin Study Group in Knee Arthroplasty. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: a randomized, double-blind clinical trial. J Thromb Haemost. 2003;1(3):425-432.

11. Krzych ŁJ, Nowacka E, Knapik P. Heparin-induced thrombocytopenia. Anaesthesiol Intensive Ther. 2015;47(1):63-76.

12. Greinacher A. Heparin-induced thrombocytopenia. N Engl J Med. 2015;373(3):252-256.

13. Akca S, Haji-Michael P, de Mendonça A, Suter P, Levi M, Vincent JL. Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30(4):753-756.